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ABSTRACT 
The International Atomic Energy Agency convened a technical meeting on environmental enteric 
dysfunction (EED) in Vienna (28th – 30th October 2015; 
https://nucleus.iaea.org/HHW/Nutrition/EED_Technical_Meeting/index.html) to bring together 
international experts in the fields of EED, nutrition and stable isotope technologies. Advances in 
stable isotope labelling techniques open up new possibilities to improve our understanding of 
gastrointestinal dysfunction and the role of the microbiota in host health. In the context of EED, 
little is known about the role gut dysfunction may play in macro- and micronutrient bioavailability 
and requirements and what the consequences may be for nutritional status and linear growth. Stable 
isotope labelling techniques have been used to assess intestinal mucosal injury and barrier function, 
carbohydrate digestion and fermentation, protein derived amino acid bioavailability and 
requirements, micronutrient bioavailability and to track microbe-microbe and microbe-host 
interactions at the single cell level. The non-invasive nature of stable isotope technologies 
potentially allows for low-hazard, field deployable tests of gut dysfunction that are applicable 
across all age-groups. The purpose of this review is to assess the state-of-the-art in the use of stable 
isotope technologies and to provide a perspective on where these technologies can be exploited to 
further our understanding of gut dysfunction in EED. 
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WHAT IS KNOWN 
• Linear growth retardation (stunting) currently affects 165 million children worldwide. 
• Nutritional interventions have had only moderate effects on linear growth.  
• Environmental enteric dysfunction (EED) is thought to be a major contributing cause of the 
failure of nutritional interventions 
 
WHAT IS NEW  
• There is a lack of functional biomarkers to assess gut dysfunction in EED. Biomarkers of 
nutrient digestion and absorption capacity, gut permeability and gut and systemic 
inflammation may allow a greater understanding of the role of EED in nutritional 
interventions. Stable isotope techniques have the potential to assess multiple aspects of gut 
dysfunction in EED.  
INTRODUCTION  
Environmental enteric dysfunction (EED) is thought to be a major contributing cause of the failure 
of nutritional interventions, be they based on micronutrient, macronutrient, and combined 
supplementation with behavioral change to normalize postnatal linear growth in populations living 
in poverty (conceptualized in Figure 1 adapted from (1)). EED, amongst other factors, is the result 
of multiple and continuous infections even in the absence of diarrhea or well defined clinical illness. 
It is posited to lead to local intestinal inflammation, altered intestinal permeability with subsequent 
bacterial translocation and immune activation. Functional aberrations in EED may include a 
reduced ability to digest macronutrients, reduced capacity to absorb essential nutrients and 
disturbances in micronutrient requirements. The role of the small intestinal microbiota is unclear but 
clearly is an important factor in the development and pathogenesis of EED. (2) In EED, the state of 
chronic immune activation compromises intestinal function and host metabolism in a way that 
derails normal prescribed linear growth patterns in affected populations.   
 
Stunting, defined as linear growth (height for age) two standard deviations below the population 
median growth curve, currently affects 25.7% of the world’s children; the total number of affected 
individuals being 165 million. (3)  Despite this burden, controlled interventions including the 
provision of food in food insecure settings, and the provision of education regarding feeding 
practices have had only moderate effects on linear growth. (4) EED is thought to be one of the 
major causes of the failure of nutritional interventions in children at risk from stunting. (5) The 
validation of this theory is however currently limited by a lack of reliable assays to measure some 
of these key parameters that are thought to be deranged in EED.  
 
Identification of better biomarkers and delineation of the key biological pathways may also guide 
better targeted interventions. Whilst markers of systemic inflammation are plentiful and well 
described, (6) markers of intestinal permeability, nutrient absorption, enterocyte metabolic capacity, 
intestinal inflammation and intestinal regeneration and repair are extremely limited. This lack of 
functional measurements severely limits our understanding of the intestinal processes that control 
nutrient bioavailability and inflammation and our ability to focus on effective interventions. Here, 
we review and discuss the potential of available stable isotope techniques as non/less-invasive and 
safe tools for advanced diagnosis and research of gastrointestinal dysfunction. 
 
THE PRINCIPLE OF USING STABLE ISOTOPES IN GASTROENTEROLOGY 
The basic principle of all stable isotope techniques in gastroenterology is to administrate a stable 
isotope-labeled compound to the body (i.e., orally, rectally or intravenously) in “trace” amounts to 
minimally disturb normal physiology, and to subsequently track the fate of the compound or its 
catabolic products in breath, tissue, feces, urine and/or blood. (7) The route of administration and 
type of isotope label and compound essentially determine which gastrointestinal function is 
assessed. Stable isotope techniques are often used to determine general epithelial function such as 
absorption and permeability. However, they can also rather precisely measure very specific 
metabolic features in the intestinal tract such as uptake of a defined micronutrient or a defined 
physiological property of intestinal microbiota members metabolizing the administered compound. 
The attraction of stable isotope based technologies in EED is their potential for non-invasive 
diagnosis in field research settings to assess a wide assortment of different components of gut 
physiology and function.  By measuring the magnitude of deviation from normal physiology in 
different epidemiologic contexts, the underlying nature and extent of pathology that underscores gut 
dysfunction in EED could be elucidated facilitating the development of effective diagnostic tests 
and interventions. 
 
BREATH TESTS AND SMALL INTESTINAL FUNCTION 
Breath tests are characterized by their non-invasive technology and as such are ideal for both 
diagnostic and longitudinal studies.  The test performance characteristics are particularly well-suited 
for studying children as testing is painless and non-invasive. (8) The most robust, safe, sensitive and 
specific stable isotope breath test devised is the 13C urea breath test (UBT) for diagnosis and 
monitoring of Helicobacter pylori (Hp). It has repeatedly been shown to have >95% sensitivity and 
specificity. (9) There are some intrinsic advantages that favor this. Firstly, when Hp is present it is 
usually the dominant microorganism in the very low pH environment of the stomach and may affect 
linear growth. (10) By thriving in the mucosa of the stomach, Hp  is also close to the site of oral 
tracer administration, leading to rapid delivery of the tracer bolus to the site of infection. As the 
tracer target moves more distal in the intestine, complex delivery formulation may be needed to 
allow for site-directed tracer delivery and there may be variations in transit time that reduce 
sensitivity and specificity of the test.  
 
Therefore, the measurement of functional characteristics in gastrointestinal tract regions distal to the 
stomach presents greater challenges with respect to targeting functional characteristics, epithelial 
damage and barrier integrity and specifically targeting pathogens. (11, 12) Several stable isotope 
breath tests for assessing gastric emptying have been designed and validated against scintigraphic 
methods. (13, 14) These tests have also been combined with non-absorbable carbohydrates, such as 
lactulose, utilizing H2 measurements in breath to determine oro-caecal transit time of a particular 
meal. (15) This in turn gives an indication and allows calculation of small intestine residency time. 
Less attention has been given to interrogating the patency of the small intestinal mucosa. A notable 
exception is the assessment of lactase deficiency or lactose malabsorption and intolerance. (16) This 
has traditionally been detected using a H2 breath test or with a combined H2/
13CO2 breath test. (17) 
 
Only a small percentage of individuals exhibit a genetically determined sucrase deficiency, much 
less than the global 70-90% prevalence for lactase deficiency. (18) This raises the possibility of 
using a 13C sucrose breath test (SBT) as a non-invasive reporter for detecting small intestinal villus 
dysfunction and damage, by targeting sucrase activity as the surrogate for quantifying the maturity 
of the absorptive capacity of the epithelium. (19, 20) A villus atrophy induced by chemotherapy is a 
common occurrence but ethical practice precludes endoscopy to assess the severity and to thus 
monitor any ameliorating interventions. The SBT has been reported in animal models and in 
childhood cancer chemotherapy and appears to act as a surrogate marker for small intestinal villus 
dysfunction and damage. (21-23) 
 
Other settings where significant small intestinal damage occurs include rotavirus infection, giardia 
lamblia infestation, coeliac disease and the endemic spectrum of EED. In many of these diseases 
and disorders the degree of absorptive impairment is not known nor easily measurable, thus its 
contribution to health and linear growth in childhood is not fully understood. Preliminary studies in 
children with acute diarrhea have shown lowered SBT response that improves as disease resolution 
occurs. (24) However in infants with EED, resolution of the small intestinal impairment in the same 
time frame did not occur. Correspondingly nor did the severity of diarrhea in these children. (25)  
 
Multiple isotope labels, targeted delivery and additional stable isotope end-points, including breath 
13CO2, will potentially move this strategy forward for understanding gut dysfunction in EED.  
 
STABLE ISOTOPES, MACRONUTRIENT BIOAVAILABILITY AND HOST RESPONSE  
Classical stable isotope dilution techniques which utilize steady-state tracer infusion protocols have 
become an essential tool for determining metabolite flux in humans. (26) However, they only focus 
on a limited number of targeted metabolites and are unsuitable for investigations in young children 
because they involve extended tracer infusions and serial blood and/or tissue sampling.  
 
Intrinsic labelling of macronutrients for human feeding studies allows for an integrative assessment 
of nutrient bioavailability. The photosynthetic pathways of carbon sequestration in plants (C3 vs. 
C4) provides natural isotopic carbon-13 (13C) enrichment in C4 plant material that is sufficient for 
measurement by isotope ratio mass spectrometry. (27) C4 plant-derived carbohydrates have been 
allowed assessment of liver glycogen oxidation (28), starch digestion and exogenous glucose 
production in adults (29, 30) and children. (31) This approach is however limited by the low signal 
to background 13C abundance. Studies using isotope labelling (enrichment) techniques have largely 
overcome these challenges. This experimental approach is exemplarily outlined for stable isotope-
labelled, plant-derived dietary compounds in Figure 2. Isotope labeling has been used to describe 
quantitative exogenous glucose production and insulin sensitivity from native plant-derived 
starches, (32) (33) (34). Beyond starch, 13C labelling has been used to determine quantitatively 
SCFA production from inulin in vivo, (35) and the extent of carbohydrate oxidation from beta-
glucan-enriched barley. (36)  These tools uniquely allow a full understanding of macronutrient 
bioavailability, requirements and metabolism and potentially provide new mechanistic insights into 
how carbohydrate requirements and metabolism are altered in EED.  
 
Of considerable interest in EED is the bioavailability of, and nutritional requirements for, protein 
derived amino acids. Energy, protein and utilizable protein availability are negatively associated 
with stunting. (37) Recent evidence has demonstrated reduced serum essential amino acids in 
stunted children. (38) What role EED plays in altering protein digestion and amino acid absorption 
and utilization is unclear at the present time.  The limitations of current techniques to assess protein 
quality an amino acid requirements have been extensively reviewed elsewhere. (39, 40) 15N-labeled 
proteins have been used to determine net postprandial protein utilization, (41, 42) by measuring of 
the kinetics of dietary N appearance in ileal contents, plasma proteins, plasma free amino acids, 
body and urinary urea, and urinary ammonia in a 13-compartment, 21 parameter model. (43) The 
complexity of the technique means it is unlikely to be widely adopted for routine applications. (39) 
In children, 13CO2 production has been used as an index of bioavailability from oxidation of 
protein-bound indicator 13C labeled amino acid whereby the extent of amino acid oxidation is 
inversely related to amino acid uptake through protein synthesis. (44)  Amino acid infusion studies 
using animals to intrinsically label specific amino acids in milk and meat protein have shown a 
dose-response of de novo muscle protein synthesis to whey protein in human feeding studies, (45) 
and that minced beef increases postprandial protein retention compared with beef steak.  (46)  A 
combined dual stable isotope study using 15N-labeled Spirulina protein and 2H-phenylalanine has 
demonstrated that protein digestibility is severely compromised in patients with cystic fibrosis. (47)  
Of significant potential is intrinsic labelling of cereal, legume and animal derived protein with 2H, 
in combination with 13C-labeled amino acids from a (pre-digested) crystalline amino-acid mixture 
having the same composition as the intact protein to assess amino acid bioavailability. (48, 49) In 
EED, this approach has the potential to assess amino acid bioavailability and requirements, taking 
into account directly the disturbances in digestion and absorption. Finally, intrinsic labelling of 
amino acids in humans using 2H2O has been used to determine the role of diet and disease on 
whole-body and tissue specific protein synthesis. (50-52)  
 
Isotope studies on lipid utilization related to gut dysfunction have largely been focused on the 
efficiency of fat digestion in the intestine. The use of 13C labeled triglyceride combined with 13CO2 
appearance in breath has been used to assess pancreatic exocrine insufficiency, (53) efficacy of 
pancreatic enzyme supplementation in disease, (54) the effects of gastrectomy on fat digestion, (55) 
and to determine how oral fat exposure, enteral lipid metabolism impacts upon postprandial 
lipemia. (56) 
 
The power of stable isotopes to trace macronutrient assimilation is unparalleled because they can be 
used in physiologically relevant settings. The challenge is to develop methodologies that are 
minimally invasive whilst yielding maximum information on how EED affects the digestion, 
absorption and utilization of the major macronutrients.    
 
  
MICRONUTRIENT ABSORPTION AND BIOAVAILABILITY 
Zinc and iron are two micronutrients of particular importance for investigations of etiology and 
therapy for EED.  Deficiencies of each nutrient are very common and disrupted absorption and 
homeostasis are considered to be likely.  Stable isotope studies have been widely applied to 
examine bioavailability of each of these nutrients from local diets, fortified and bio-fortified foods, 
and from supplements in vulnerable populations.  Great potential exists for detailed studies in 
children with EED to better characterize the extent and impact of the condition on micronutrient 
utilization. 
 
Zinc 
Three stable isotopes of zinc (70Zn, 67Zn, and 68Zn) have low enough natural abundance to be useful 
as tracers of zinc homeostasis. (57) The most commonly applied approach to measurement of zinc 
absorption is the “dual isotope tracer ratio” method, which involves oral administration of one 
isotope and intravenous administration of another isotope.  Measurement of the ratio of the isotope 
enrichment in plasma or urine several days later provides a determination of the fractional 
absorption of zinc; multiplication of this times the amount of ingested zinc yields the amount of 
absorbed zinc.  Oral isotope is ideally administered with all meals of the day to yield total daily 
absorbed zinc; administration in post-absorptive state with a standardized dose can provide estimate 
of absorption “capacity.”  Excretion of endogenously secreted zinc in the intestine, a critical aspect 
of zinc homeostasis can also be estimated by the “isotope dilution” method, by determination of the 
ratio of the amount of an intravenously administered isotope in feces to that in urine over the same 
time period. (58) Since the endogenous fecal zinc appears to be more reflective of host zinc status 
than the absorption efficiency, simplified approaches to its determination are being explored (e.g. 
utilizing partial instead of complete fecal collections).   The size of the exchangeable Zn pools 
(EZP), a putative index of zinc status, can also be estimated by measurement of urine enrichment of 
an intravenously administered stable isotope. All of these approaches to zinc homeostasis have been 
safely applied in pregnant women, infants and young children.  Although administration and 
collection procedures require meticulous care and attention to detail, they have been successfully 
applied in many austere environments. (59)   
As appreciation of the complexity of EED has been increasingly recognized, it also seems likely 
that micronutrient requirements are higher, due to impaired absorption and/or increased losses.  
Several approaches using zinc stable isotopes are relevant: studies comparing absorption in children 
with and without EED; measuring absorption from a range of doses to identify that which is high 
enough absorption to meet “pathophysiologic requirements”; and studies to document endogenous 
intestinal losses in EED.   As a potential biomarker of zinc status and response to zinc interventions, 
EZP is expensive, but it could usefully be measured in subsets of subjects participating in 
intervention trials to evaluate response to intervention and to link to functional outcomes. 
 
Iron 
The gold standard for measuring iron absorption and bioavailability from foods or supplements, 
both in healthy individuals and those with malabsorption, is the iron stable-isotope technique based 
on erythrocyte incorporation of the stable isotope labels 14 days after intake. (60) Three stable 
isotopes of iron are commonly used (54Fe, 57Fe and 58Fe). Labeled iron compounds (e.g., ferrous 
sulfate, ferrous fumarate, NaFeEDTA) can be prepared from isotopically enriched elemental iron. 
The labels are added to test meals or supplements that are fed to fasted human subjects. (61) The 
labels mix with the total non-heme iron pool from the meal or supplement in the stomach and are 
mainly absorbed in the upper duodenum. (62) Either within- or between subject designs can be 
used. Fourteen days after the administration of the test meals, on the basis of the shift in the iron 
isotope ratios in the blood samples measured by mass spectrometry and the amount of iron 
circulating in the body, the amounts of the labeled iron compounds in the blood and thereby 
fractional absorption of the iron is calculated. (63) Because these techniques involve no 
radioactivity, they can be used in infants and young children with no health risk. (60, 64) 
Stable iron isotopes could be used to quantify, with high precision, iron absorption and 
bioavailability from diets, lipid-based nutritional supplements and/or micronutrient powders in 
children with EED. This would provide insight into the severity of iron malabsorption and the 
etiology of anemia in EED, as well as assessing changes in absorption in children recovering from 
EED.  
 
SINGLE CELL ISOTOPE METHODS FOR PROBING MICROBIOTA-GUT FUNCTION 
Spatially highly resolved isotope imaging emerges as an important complement to common stable 
isotope labelling techniques, which essentially measure whole body or population averages that 
mask relevant differences between individual cells. In working towards a complete understanding 
of a biological system, it is important to get a more refined understanding of the contributions of its 
individual parts, the cells, and their interactions with each other. (65, 66) Use of high-end 
microspectroscopy and secondary ion mass spectrometry instruments for stable isotope analytics 
allows dissecting the physiological function and metabolic heterogeneity of subpopulations of cells 
that constitute e.g. a tissue or the diverse species of the complex human microbiota. This is of 
particular importance for the gastrointestinal tract, where metabolic processes are extremely 
complex and dynamic because of the temporally and spatially variable presence of various diet- or 
host-derived substrates, and the diverse microbial populations and host cells that metabolize those 
substrates. (67) With these single-cell stable-isotope methods at hand, one can now start 
disassembling the manifold synergistic and antagonistic physiological interactions among 
individual cells of the intestinal microbiota and the host tissue and identifying key cellular 
populations that determine the flow of nutrients and energy to and from the host. As with any other 
stable isotope-labeling approach, the type of isotope (mostly 13C, 15N, but also 18O or 2H) and 
substrate, and how the labeled substrate is administered determines which physiological function is 
being investigated. The incorporation of the isotope label into cellular components of a microbial 
cell is subsequently quantified with specialized instruments, such as a confocal Raman 
microspectroscopy, which has a lateral resolution of approximately 1 µm, or a NanoSIMS, a 
secondary ion mass spectrometer for parallel detection of up to seven ion masses and nanoscale 
spatial resolution. Isotope analysis can be directly combined with fluorescence in situ hybridization 
(FISH) for identification of microbial cells. (67) Selected applications include identification of 
microbes that forage on host-derived 13C/15N-labeled protein compounds (68) and use of heavy 
water (2H2O) as a general marker for cellular activity. (69) While these single-cell methods were 
initially developed and applied in animal models, stable isotope analysis of individual cells can be 
readily performed on fecal samples or tissue biopsies obtained from patients that are subject to 
some of the more routine stable isotope tests mentioned above. Single cell analysis by Raman 
microspectroscopy or NanoSIMS is inherently time-consuming and thus essentially not tailored to 
routine diagnostics in gastroenterology. Instead, these advanced research tools will contribute to a 
high-resolution picture of the complex physiological processes in gastrointestinal tract, particularly 
into the role of individual members of the resident microbiota in EED. 
 
CHALLENGES AND FUTURE PERSPECTIVES 
The potential for stable isotope based techniques to provide non-invasive, possibly low cost and 
field deployable diagnostic tests in gut dysfunction is a tantalizing prospect. However, significant 
research is still required to realize this prospect if we are to make use of stable isotopes in a setting 
like EED for diagnostic or disease stratification purposes. There are challenges to overcome but the 
opportunities that could be realized are profound. 
 
Challenges: integrating high-end, high-cost mass spectrometry technologies in limited resource 
settings may be seen as a significant barrier to implementing stable isotope technologies in a 
community setting. Solutions are beginning to emerge with field deployable infrared based 
techniques for measuring isotopic abundance in select metabolites (mainly CO2 and H2O). Careful 
selection and validation of appropriate tracers for appropriate end-point measurements with robust 
clinical outcomes is required. Techniques for single-cell investigations will remain focused in well-
resourced and competent research laboratories but because such techniques can add considerable 
insights into microbe and host physiology, they need to be embraced to provide a greater 
understanding of EED. 
 
Future Perspectives: The adoption of stable isotope based micronutrient bioavailability assays in 
intervention studies in EED will continue to add considerable insight into micronutrient utilization 
and the efficacy of fortification trials. Research using combinations of tests (stable isotopes and 
biomarkers) are needed to assess multiple aspects of gut dysfunction (mucosal injury, digestion, 
permeability/barrier function and microbiota function) simultaneously. The potential for intrinsic 
labelling of food to dissect how macronutrient uptake and utilization are affected in EED holds 
significant promise. These opportunities are outlined in Figure 3. Whether this integrated 
physiological view has the potential to allow stratification of EED into relative risk of stunted 
growth remains to be seen but stratification based on biomarkers has yielded significantly 
improvements in the management and treatment in other contexts, for example cancer and 
cardiovascular disease. Stable isotopes add essential functional measurements to the existing array 
of biomarkers and have significant potential to be applied in diseases where gut dysfunction has an 
important role. 
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Figure Legends 
Figure 1. Repeated enteric infections coupled with altered mucosal immune responses and 
macronutrient/micronutrient absorption and availability are major determinants of gut dysfunction 
observed in environmental enteric dysfunction (EED). The role of the gut microbiome requires 
further investigation. Together, these may be important drivers of the outcomes observed in EED 
such as growth faltering, reduced vaccine response and impairments in cognitive development.  
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Figure 2. The 3 domains of a human stable isotope labeling experiment using labeled 
macronutrients. Stable isotope labelling of macronutrients from plant sources has been achieved by 
both 13CO2 enrichment of the plant atmosphere, use of 
15N (nitrate, ammonium) fertilizers or 2H2O 
labelling of plant feed water. Deuterium labelling lends itself to both low and highly enriched plant 
products whereas carbon labelling is mostly (but not exclusively) restricted to low enriched 
products. The labelling strategy has consequences for the technologies required to measure isotopic 
enrichment in target metabolites. Highly enriched metabolites (>1 atom percent excess) are 
amenable to “organic” mass spectrometry and NMR. Low enriched metabolites are largely 
restricted to isotope ratio mass spectrometry approaches. Once a labelling protocol has been 
undertaken, the plant can be used whole, or fractionated into macronutrients and incorporated into 
foods (the food matrix remaining unlabeled but target macronutrients labeled within the food). Once 
ingested, the analysis required depends on the question being asked. If rate and extent of oxidation 
are the only requirements (as in 13C breath tests), collection of expired breath 13CO2 over time is 
sufficient. If molecular information is required about metabolites from digestion and absorption of a 
labeled macronutrient, then compound specific isotope analysis is necessary, often through serial 
blood sampling to gather time-course information. Such information may also be available through 
urine metabolite excretion. In order to derive true molecular flux information, a second tracer 
administered (orally or i.v.) in a known quantity may sometimes be required to account for the 
unknown fraction of labeled metabolites entering a biological pool from macronutrient digestion 
and absorption. Finally fecal microbiota isotope sequestration yields information on nutrient uptake 
and microbial activity specific to the labeled substrate. 
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Figure 3. Associated with EED are a host of functional aberrations that potentially allow for 
diagnostic tests in EED. Only some of these aberrations are suitable for the application of stable 
isotope technologies. The 13C-sucrose breath test (SBT) has potential to assess mucosal injury 
(villus atrophy). Characterizing the composition gut microbiome in EED will benefit from applying 
the full suite of “omics” technologies (meta-omics). Characterizing the function of members of the 
microbiota will require stable isotope probing (SIP) and single cell technologies. Developing tools 
to describe nutrient requirements (carbohydrate (CHO), protein (PRO) and micronutrients (Zn, Fe)) 
will require development of robust stable isotope protocols. Characterizing inflammation relies on 
biomarkers such as alpha-1antitrypsin (AIAT), myeloperoxidase (MPO) and possibly calprotectin 
for intestinal inflammation and established biomarkers such as C-reactive protein (CRP) for 
systemic inflammation. Characterizing gut permeability relies largely on established sugar 
absorption/urinary excretion tests. Therefore, of significant potential for the application of stable 
isotope technologies is the assessment of mucosal injury, gut microbiota function and nutrient 
requirements.  
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